MedTrace Logo

Regional Multicenter Study to Evaluate Tolerability and Efficacy of TAF/FTC/RPV Combination (ODEFSEY ®) in Prevention of Sexual or Blood Exposure to HIV

NCT03451032 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2019-08-28

No results posted yet for this study

Summary

Prospective, multicenter study to evaluate tolerability, adherence and efficacy of a 28-day course of TAF/FTC/RPV, an HIV post-exposure prophylaxis after a potential sexual or blood exposure to HIV.

At baseline, participants are prescribed TAF/FTC/RPV and a blood test. At W6, all participants are contacted by phone to evaluate completeness and tolerability of the TAF/FTC/RPV regimen.

Conditions

Interventions

OTHER

Non Interventional Study

Non Interventional Study

Sponsors & Collaborators

  • Nantes University Hospital

    lead OTHER

Principal Investigators

  • Bénédicte BONNET, Dr · Nantes University Hospital

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-15
Primary Completion
2019-03-15
Completion
2019-03-15

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03451032 on ClinicalTrials.gov